FAMICORD AG (V3V.DE) Stock Fundamental Analysis
FRA:V3V - Deutsche Boerse Ag - DE000A0BL849 - Common Stock - Currency: EUR
Taking everything into account, V3V scores 3 out of 10 in our fundamental rating. V3V was compared to 26 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of V3V have multiple concerns. V3V is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
V3V had positive earnings in the past year.
In the past year V3V had a positive cash flow from operations.
In multiple years V3V reported negative net income over the last 5 years.
Of the past 5 years V3V 4 years had a positive operating cash flow.
1.2 Ratios
V3V has a Return On Assets (1.61%) which is comparable to the rest of the industry.
V3V has a better Return On Equity (10.63%) than 69.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.61% | ||
| ROE | 10.63% | ||
| ROIC | N/A |
ROA(3y)-7.04%
ROA(5y)-3.48%
ROE(3y)-60.2%
ROE(5y)-34.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 3.20%, V3V is doing good in the industry, outperforming 65.38% of the companies in the same industry.
Looking at the Gross Margin, with a value of 36.66%, V3V is in line with its industry, outperforming 57.69% of the companies in the same industry.
In the last couple of years the Gross Margin of V3V has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 3.2% | ||
| GM | 36.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.67%
GM growth 5Y-8.9%
2. Health
2.1 Basic Checks
V3V does not have a ROIC to compare to the WACC, probably because it is not profitable.
V3V has more shares outstanding than it did 1 year ago.
The number of shares outstanding for V3V has been increased compared to 5 years ago.
V3V has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.53, we must say that V3V is in the distress zone and has some risk of bankruptcy.
V3V has a Altman-Z score of 0.53. This is amonst the worse of the industry: V3V underperforms 80.77% of its industry peers.
V3V has a debt to FCF ratio of 2.09. This is a good value and a sign of high solvency as V3V would need 2.09 years to pay back of all of its debts.
The Debt to FCF ratio of V3V (2.09) is better than 96.15% of its industry peers.
V3V has a Debt/Equity ratio of 0.56. This is a neutral value indicating V3V is somewhat dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.56, V3V belongs to the best of the industry, outperforming 80.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | 2.09 | ||
| Altman-Z | 0.53 |
ROIC/WACCN/A
WACC6.19%
2.3 Liquidity
V3V has a Current Ratio of 0.76. This is a bad value and indicates that V3V is not financially healthy enough and could expect problems in meeting its short term obligations.
V3V has a Current ratio of 0.76. This is in the lower half of the industry: V3V underperforms 76.92% of its industry peers.
A Quick Ratio of 0.70 indicates that V3V may have some problems paying its short term obligations.
With a Quick ratio value of 0.70, V3V is not doing good in the industry: 65.38% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.76 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
V3V shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 109.51%, which is quite impressive.
The Revenue has been growing slightly by 7.73% in the past year.
Measured over the past years, V3V shows a very strong growth in Revenue. The Revenue has been growing by 30.44% on average per year.
EPS 1Y (TTM)109.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
Revenue 1Y (TTM)7.73%
Revenue growth 3Y57.65%
Revenue growth 5Y30.44%
Sales Q2Q%8.91%
3.2 Future
V3V is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.64% yearly.
V3V is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.88% yearly.
EPS Next Y58.33%
EPS Next 2Y35.4%
EPS Next 3Y32.64%
EPS Next 5YN/A
Revenue Next Year9.33%
Revenue Next 2Y8.01%
Revenue Next 3Y6.85%
Revenue Next 5Y2.88%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 36.43, which means the current valuation is very expensive for V3V.
69.23% of the companies in the same industry are cheaper than V3V, based on the Price/Earnings ratio.
V3V's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.51.
V3V is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.43 | ||
| Fwd PE | N/A |
4.2 Price Multiples
V3V's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. V3V is more expensive than 61.54% of the companies in the same industry.
V3V's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. V3V is cheaper than 61.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.02 | ||
| EV/EBITDA | 10.69 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
V3V's earnings are expected to grow with 32.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.62
PEG (5Y)N/A
EPS Next 2Y35.4%
EPS Next 3Y32.64%
5. Dividend
5.1 Amount
V3V does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:V3V (8/7/2025, 7:00:00 PM)
5.1
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.26%
Inst Owner ChangeN/A
Ins Owners58.45%
Ins Owner ChangeN/A
Market Cap89.96M
Analysts84
Price Target6.63 (30%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.17%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.43 | ||
| Fwd PE | N/A | ||
| P/S | 1.12 | ||
| P/FCF | 10.02 | ||
| P/OCF | 7.43 | ||
| P/B | 3.7 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.69 |
EPS(TTM)0.14
EY2.75%
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)0.51
FCFY9.98%
OCF(TTM)0.69
OCFY13.46%
SpS4.57
BVpS1.38
TBVpS-1.68
PEG (NY)0.62
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.61% | ||
| ROE | 10.63% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 3.2% | ||
| GM | 36.66% | ||
| FCFM | 11.13% |
ROA(3y)-7.04%
ROA(5y)-3.48%
ROE(3y)-60.2%
ROE(5y)-34.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.67%
GM growth 5Y-8.9%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | 2.09 | ||
| Debt/EBITDA | 1.65 | ||
| Cap/Depr | 35.61% | ||
| Cap/Sales | 3.89% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 147.25% | ||
| Profit Quality | 347.6% | ||
| Current Ratio | 0.76 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 0.53 |
F-Score7
WACC6.19%
ROIC/WACCN/A
Cap/Depr(3y)60.39%
Cap/Depr(5y)47.49%
Cap/Sales(3y)7.53%
Cap/Sales(5y)6.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)109.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
EPS Next Y58.33%
EPS Next 2Y35.4%
EPS Next 3Y32.64%
EPS Next 5YN/A
Revenue 1Y (TTM)7.73%
Revenue growth 3Y57.65%
Revenue growth 5Y30.44%
Sales Q2Q%8.91%
Revenue Next Year9.33%
Revenue Next 2Y8.01%
Revenue Next 3Y6.85%
Revenue Next 5Y2.88%
EBIT growth 1Y97.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year562.86%
EBIT Next 3Y100.95%
EBIT Next 5Y74.16%
FCF growth 1Y198.46%
FCF growth 3Y20.6%
FCF growth 5Y6%
OCF growth 1Y520.19%
OCF growth 3Y37.37%
OCF growth 5Y14.78%